NCT03427632

Role of Percutaneous Vertebroplasty in Treatment of Vertebral Tumors

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 11 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 1 Year – 100 Years
• Healthy volunteers: —

Summary

Percutaneous vertebroplasty is a new technique to strengthen bone and reduce pain for patients with vertebral tumors

Detailed description

Destructive vertebral lesions are a common in metastatic disease, multiple myeloma and lymphoma. Symptoms are caused by pathologic fracture consequences secondary to vertebral destruction, development of spinal instability and compression of adjacent neurological elements. Nonoperative treatments include radiotherapy, hormone therapy, cytotoxic drugs which are effective to halt the osteolytic process and reverse the neurological compromise, however; they cannot provide stability or relieve pain or cord compression. Surgical management options including vertebrectomy, reconstruction with a cage or PMMA bone cement, and stabilization with pedicle screws can restore spinal canal support and neurological functions also control pain, however; usually associated with high postoperative morbidity and mortality. Also not advisable for multifocal spinal disease. Percutaneous vertebroplasty is a new technique to strengthen bone and reduce pain. It is percutaneous, minimally invasive, image-guided procedure that involves injection of radio-opaque bone cement into a partially collapsed vertebral body, in an effort to provide stability and pain relief. The exact mechanism of pain relief remains unclear. Proposed theories include more favourable biomechanics after cement strengthening, chemical toxicity and exothermic effect of cement polymerization on nerve endings.

Conditions

• Bone Tumor

Interventions

Type	Name	Description
DRUG	Bone Cements	patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra

Timeline

• Start date: 2018-03-01
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2018-02-09
• Last updated: 2018-02-09

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study